Blood
Articles in this Issue
Immune cell dynamics following rituximab and epcoritamab as first-line therapy for patients with high-tumor burden follicular lymphoma
Abstract Introduction: Epcoritamab (epco) is a CD3xCD20 bispecific antibody that achieves high objective response rates...
Platelet-activating antibodies to the chemokine, platelet factor 4, in cerebral malaria differ from those in heparin-induced thrombocytopenia and vaccine-induced thrombotic thrombocytopenia.
Abstract Background: Cerebral malaria (CM) is a severe complication of Plasmodium falciparum infection, primarily affecting children, with a...
Readability & quality of large language model responses in CAR-T patient education
Abstract Introduction Large language models (LLMs) are a promising generative artificial intelligence tool for oncologists to leverage in wr...
Long-term outcomes of a chemotherapy-free regimen of concomitant blinatumomab and inotuzumab ozogamicin in older patients with Philadelphia negative B-cell acute lymphoblastic leukemia
Abstract Background Older adults with B-cell acute lymphoblastic leukemia (B-ALL) represent a high-risk population with poor outcomes. Effor...
Thrombotic outcomes in sickle cell disease patients treated with crizanlizumab with or without hydroxyurea: A real-world retrospective cohort analysis using the trinetx database
Abstract Introduction: Crizanlizumab, a humanized monoclonal antibody targeting P-selectin, was approved by the FDA in 2019 to reduce the fr...
Sars-cov-2 NSP10 protein activates the p38 MAPK signaling pathway by downregulating DUSP2 to trigger cytokine storm
Abstract Background Novel Coronavirus Infections (COVID-19) is a global epidemic caused by the SARS-CoV-2 virus. Due to the high variability...
Toxicities on the E1910 phase III randomized trial of blinatumomab plus chemotherapy in adults with BCR:ABL-1 negative acute lymphoblastic leukemia
Abstract E1910 evaluated the addition of blinatumomab to chemotherapy in adults with B-acute lymphoblastic leukemia (ALL). The addition of b...
Early dflc response for predicting complete hematological response in patients with AL amyloidosis: A multi-center prospective observational study
Abstract Introduction The treatment of AL amyloidosis primarily relies on anti-plasma cell therapy and supportive care. Daratumumab, bortezo...
Treatment-free remission in patients with chronic myeloid leukemia following the second discontinuation of tyrosine kinase inhibitors
Abstract Introduction Tyrosine kinase inhibitors (TKIs) discontinuation has been considered for chronic myeloid leukemia (CML) patients with...
Phase-3 study of vamotinib (PF-114) versus high-dose imatinib
Abstract Background Vamotinib (PF-114), an oral tyrosine kinase-inhibitor (TKI) is active against wild-type and BCR::ABL1 variants. Whether...
ATRA and ATO can induce remission in NPM1-mutated AML: First clinical report of a chemo-free strategy
Abstract Background:Acute myeloid leukemia (AML) with NPM1 mutation may present with an immunophenotype mimicking acute promyelocytic leukem...
Efficacy and safety of mitoxantrone hydrochloride liposome combined with pegaspargase in the treatment of extranodal NK/T-cell lymphoma
Abstract Background: Extranodal Natural Killer/T-cell Lymphoma (ENKTL) is a highly aggressive non-Hodgkin lymphoma origi...
Trends in mortality and comorbidity of myelodysplastic syndromes among u.S.adults with heart failure: A CDC wonder-based analysis, 1999–2023
Abstract Background: Myelodysplastic syndromes, a group of disorders causing ineffective hematopoiesis, leads to an increased risk of acute...
Real-world outcomes of frontline polatuzumab-rchp and impact of frailty in older adults with diffuse large B-cell lymphoma
Abstract Introduction Pola-RCHP is a new standard of care (SOC) in the frontline (1L) treatment of DLBCL. While clinical trial data support...
Circulating tumor DNA-based minimal residual disease assessment predicts progression-free survival in diffuse large B-cell lymphoma: A systematic review and meta-analysis
Abstract Circulating Tumor DNA-Based Minimal Residual Disease Assessment Predicts Progression-Free Survival in Diffuse Large B-Cell Lymphoma: A Systematic Review...
Efficacy and safety of azacitidine, venetoclax combined with gha priming regimen in the treatment of adult refractory and relapsed acute myeloid leukemia: A prospective single-arm multicenter study
Abstract Objective: To investigate the efficacy and safety of azacitidine, venetoclax combined with GHA priming regimen in the treatment of...
Replicative stress-induced aging of hematopoietic stem progenitor cells increases oncogenic mutation burden and incidence of myelodysplasia in sickle cell disease mice
Abstract Introduction: Sickle cell disease (SCD) affects millions globally, results in vascular occlusions, chronic organ damage and early d...
Navigating classical Hodgkin lymphoma in a patient with DIAPH1 deletion syndrome: Diagnostic and therapeutic challenges in a rare immuno-genetic context
Abstract DIAPH1 encodes for formin diaphanous homolog 1, a protein fundamental to cytoskeletal organisation, cell division, neurodevelopment...
Blood cell counts and the duffy null phenotype: Beyond neutropenia
Abstract Background: The absence of Duffy antigen expression on red blood cells, known as the Duffy null phenotype [Fy(a-b-)], results from...
Aberrant lymphocytes are associated with increased inflammatory complications following CAR-T infusion
Abstract Cytokine release syndrome (CRS), neurotoxicity (eg, ICANS), and prolonged neutropenia constitute major complications of CAR-T thera...
Thrombopoietin inhibition abrogates JAK2V617F clonal expansion in a murine model of myeloproliferative neoplasm
Abstract Background: Myeloproliferative neoplasms (MPN) are a heterogenous group of hematopoietic stem cell (HSC)-derived disorders resultin...
BTKi in the peri-infusion period in lymphoma patients receiving CD19 CAR T cell therapy
Abstract Introduction With evidence for beneficial effects on CAR T cell phenotype and the potential for mitigation of cytokine release synd...
Clinical implementation readiness of machine learning in hematologic malignancy imaging: A scoping review and evidence-based framework
Abstract Background Machine learning (ML) tools for hematologic malignancy imaging show strong technical performance, yet remarkably few hav...
Evolution of myeloma bone disease over time: Comparison of selected biomarkers in MGUS, SMM and active MM
Abstract Background: Myeloma bone disease (MBD) is a hallmark of multiple myeloma (MM) and is present in up to 80% of newly diagnosed patient...
Aspirin therapy in myelofibrosis: Real-world clinical practice and outcomes in 215 consecutive patients
Abstract BackgroundAntiplatelet agents are a cornerstone of therapy in myeloproliferative neoplasms (MPN) for reduction of thrombotic risk....